Neurological Sciences

, Volume 32, Supplement 1, pp 95–98

Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies

  • Pietro Cortelli
  • Gianni Allais
  • Vincenzo Tullo
  • Chiara Benedetto
  • Dario Zava
  • Stefano Omboni
  • Gennaro Bussone
Symposium - Antimigraine Treatment: Preferences and Optimization


The objective of the study is to systematically review the efficacy and safety of frovatriptan (F) versus rizatriptan (R), zolmitriptan (Z) and almotriptan (A), through a pooled analysis of three individual studies. 414 subjects with a history of migraine with or without aura (IHS criteria) were randomized to F 2.5 mg or R 10 mg (study 1), F 2.5 mg or Z 2.5 mg (study 2), and F 2.5 mg or A 12.5 mg (study 3). The studies had an identical multicenter, randomized, double blind, cross-over design, with each of the two treatment periods lasting not more than 3 months. The number of pain free (PF) and pain relief (PR) episodes at 2 h, and the number of sustained pain free (SPF) and recurrent episodes within the 48 h were the efficacy endpoints. 346 patients were included in the intention-to-treat analysis. Rate of PF episodes at 2 h was 30% with F and 34% with comparators (p = NS). PR episodes at 2 h were 55% for F and 59% for comparators (p = NS). SPF episodes at 48 h were also similar between the two groups (22% F vs. 21% comparators). Rate of recurrence was significantly (p < 0.001) lower under F (27 vs. 40% comparators). Drug-related adverse events were significantly (p < 0.05) less under F, particularly cardiovascular symptoms. Our systematic analysis of individual studies suggests that F has a similar immediate efficacy, but a more sustained effect and a better tolerability than R, Z and A.


Migraine Frovatriptan Rizatriptan Zolmitriptan Almotriptan 


  1. 1.
    Balbisi EA (2004) Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. Int J Clin Pract 58:695–705PubMedCrossRefGoogle Scholar
  2. 2.
    Buchan P, Wade A, Ward C, Oliver SD, Stewart AJ, Freestone S (2002) Frovatriptan: a review of drug-drug interactions. Headache 42(Suppl 2):S63–S73PubMedCrossRefGoogle Scholar
  3. 3.
    Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259–1287PubMedCrossRefGoogle Scholar
  4. 4.
    Poolsup N, Leelasangaluk V, Jittangtrong J, Rithlamlert C, Ratanapantamanee N, Khanthong M (2005) Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials. J Clin Pharm Ther 30:521–532PubMedCrossRefGoogle Scholar
  5. 5.
    Cady RK, Banks J, Jones BA, Campbell J (2009) Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination. Curr Med Res Opin 25:2711–2721PubMedGoogle Scholar
  6. 6.
    Wallasch TM (2010) Frovatriptan in the practice of office-based neurologists/pain therapists: results of postmarketing surveillance study ALADIN. Adv Ther 27:56–62PubMedCrossRefGoogle Scholar
  7. 7.
    Kelman L, Harper SQ, Hu X, Campbell JC (2010) Treatment response and tolerability of frovatriptan in patients reporting short- or long-duration migraines at baseline. Curr Med Res Opin 26:2097–2104PubMedCrossRefGoogle Scholar
  8. 8.
    Savi L, Omboni S, Lisotto C, Zanchin G, Ferrari MD, Zava D, Pinessi L (2010) A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. J Headache Pain (Epub ahead of print)Google Scholar
  9. 9.
    Tullo V, Allais G, Ferrari MD, Curone M, Mea E, Omboni S, Benedetto C, Zava D, Bussone G (2010) Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study. Neurol Sci 31(Suppl 1):S51–S54PubMedCrossRefGoogle Scholar
  10. 10.
    Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D, Panascia B, Savi L, Pini LA, Sances G, Santoro P, Zanchin G, Omboni S, Ferrari MD, Fierro F (2011) A double-blind, randomized, multi center, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain (Epub ahead of print)Google Scholar
  11. 11.
    Headache Classification Subcommittee of the International Headache Society (2004) The International Classification of Headache Disorders, 2nd edn. Cephalalgia 24(Suppl 1):9–160Google Scholar
  12. 12.
    Tepper SJ, Rapoport AM, Sheftell FD (2002) Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 59:1084–1088PubMedCrossRefGoogle Scholar
  13. 13.
    Loder E (2010) Triptan therapy in migraine. N Engl J Med 363:63–70PubMedCrossRefGoogle Scholar
  14. 14.
    Ferrari MD, Goadsby PJ, Roon KI, Lipton RB (2002) Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22:633–658PubMedCrossRefGoogle Scholar
  15. 15.
    Adelman JU, Belsey J (2003) Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. J Manag Care Pharm 9:45–52PubMedGoogle Scholar
  16. 16.
    Ryan R, Géraud G, Goldstein J, Cady R, Keywood C (2002) Clinical efficacy of frovatriptan: placebo-controlled studies. Headache 42(Suppl 2):S84–S92PubMedCrossRefGoogle Scholar
  17. 17.
    Géraud G, Keywood C, Senard JM (2003) Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 43:376–388PubMedCrossRefGoogle Scholar
  18. 18.
    Géraud G, Spierings EL, Keywood C (2002) Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache 42(Suppl 2):S93–S99PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Pietro Cortelli
    • 1
  • Gianni Allais
    • 2
  • Vincenzo Tullo
    • 3
  • Chiara Benedetto
    • 2
  • Dario Zava
    • 4
  • Stefano Omboni
    • 5
  • Gennaro Bussone
    • 3
  1. 1.Clinica Neurologica, Dipartimento di Scienze NeurologicheUniversità di BolognaBolognaItaly
  2. 2.Department of Gynecology and Obstetrics, Women’s Headache CenterUniversity of TorinoTurinItaly
  3. 3.Dipartimento di Neuroscienze ClinicheIstituto Nazionale Neurologico Carlo BestaMilanItaly
  4. 4.Istituto Lusofarmaco d’ItaliaMilanItaly
  5. 5.Italian Institute of TelemedicineVareseItaly

Personalised recommendations